Cargando…

Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis

INTRODUCTION: Bone metastasis is the most common complication of advanced breast cancer. The associated cancer-induced bone disease is treated with bone-sparing agents like zoledronic acid. Clinical trials have shown that zoledronic acid also reduces breast cancer recurrence in bone; potentially by...

Descripción completa

Detalles Bibliográficos
Autores principales: Haider, Marie-Therese, Holen, Ingunn, Dear, T. Neil, Hunter, Keith, Brown, Hannah K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127787/
https://www.ncbi.nlm.nih.gov/pubmed/24971713
http://dx.doi.org/10.1016/j.bone.2014.06.023
_version_ 1782330060660801536
author Haider, Marie-Therese
Holen, Ingunn
Dear, T. Neil
Hunter, Keith
Brown, Hannah K.
author_facet Haider, Marie-Therese
Holen, Ingunn
Dear, T. Neil
Hunter, Keith
Brown, Hannah K.
author_sort Haider, Marie-Therese
collection PubMed
description INTRODUCTION: Bone metastasis is the most common complication of advanced breast cancer. The associated cancer-induced bone disease is treated with bone-sparing agents like zoledronic acid. Clinical trials have shown that zoledronic acid also reduces breast cancer recurrence in bone; potentially by modifying the bone microenvironment surrounding disseminated tumour cells. We have characterised the early effects of zoledronic acid on key cell types of the metastatic niche in vivo, and investigated how these modify the location of breast tumour cells homing to bone. METHODS: Female mice were treated with a single, clinically achievable dose of zoledronic acid (100 μg/kg) or PBS. Bone integrity, osteoclast and osteoblast activity and number/mm trabecular bone on 1, 3, 5 and 10 days after treatment were assessed using μCT, ELISA (TRAP, PINP) and bone histomorphometry, respectively. The effect of zoledronic acid on osteoblasts was validated in genetically engineered mice with GFP-positive osteoblastic cells. The effects on growth plate cartilage were visualised by toluidine blue staining. For tumour studies, mice were injected i.c. with DID-labelled MDA-MB-231-NW1-luc2 breast cancer cells 5 days after zoledronic acid treatment, followed by assessment of tumour cell homing to bone and soft tissues by multiphoton microscopy, flow cytometry and ex vivo cultures. RESULTS: As early as 3 days after treatment, animals receiving zoledronic acid had significantly increased trabecular bone volume vs. control. This rapid bone effect was reflected in a significant reduction in osteoclast and osteoblast number/mm trabecular bone and reduced bone marker serum levels (day 3–5). These results were confirmed in mice expressing GFP in osteoblastic linage cells. Pre-treatment with zoledronic acid caused accumulation of an extra-cellular matrix in the growth plate associated with a trend towards preferential [1] homing of tumour cells to osteoblast-rich areas of bone, but without affecting the total number of tumour cells. The number of circulating tumour cells was reduced in ZOL treated animals. CONCLUSION: A single dose of zoledronic acid caused significant changes in the bone area suggested to contain the metastatic niche. Tumour cells arriving in this modified bone microenvironment appeared to preferentially locate to osteoblast-rich areas, supporting that osteoblasts may be key components of the bone metastasis niche and therefore a potential therapeutic target in breast cancer.
format Online
Article
Text
id pubmed-4127787
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-41277872014-09-01 Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis Haider, Marie-Therese Holen, Ingunn Dear, T. Neil Hunter, Keith Brown, Hannah K. Bone Original Full Length Article INTRODUCTION: Bone metastasis is the most common complication of advanced breast cancer. The associated cancer-induced bone disease is treated with bone-sparing agents like zoledronic acid. Clinical trials have shown that zoledronic acid also reduces breast cancer recurrence in bone; potentially by modifying the bone microenvironment surrounding disseminated tumour cells. We have characterised the early effects of zoledronic acid on key cell types of the metastatic niche in vivo, and investigated how these modify the location of breast tumour cells homing to bone. METHODS: Female mice were treated with a single, clinically achievable dose of zoledronic acid (100 μg/kg) or PBS. Bone integrity, osteoclast and osteoblast activity and number/mm trabecular bone on 1, 3, 5 and 10 days after treatment were assessed using μCT, ELISA (TRAP, PINP) and bone histomorphometry, respectively. The effect of zoledronic acid on osteoblasts was validated in genetically engineered mice with GFP-positive osteoblastic cells. The effects on growth plate cartilage were visualised by toluidine blue staining. For tumour studies, mice were injected i.c. with DID-labelled MDA-MB-231-NW1-luc2 breast cancer cells 5 days after zoledronic acid treatment, followed by assessment of tumour cell homing to bone and soft tissues by multiphoton microscopy, flow cytometry and ex vivo cultures. RESULTS: As early as 3 days after treatment, animals receiving zoledronic acid had significantly increased trabecular bone volume vs. control. This rapid bone effect was reflected in a significant reduction in osteoclast and osteoblast number/mm trabecular bone and reduced bone marker serum levels (day 3–5). These results were confirmed in mice expressing GFP in osteoblastic linage cells. Pre-treatment with zoledronic acid caused accumulation of an extra-cellular matrix in the growth plate associated with a trend towards preferential [1] homing of tumour cells to osteoblast-rich areas of bone, but without affecting the total number of tumour cells. The number of circulating tumour cells was reduced in ZOL treated animals. CONCLUSION: A single dose of zoledronic acid caused significant changes in the bone area suggested to contain the metastatic niche. Tumour cells arriving in this modified bone microenvironment appeared to preferentially locate to osteoblast-rich areas, supporting that osteoblasts may be key components of the bone metastasis niche and therefore a potential therapeutic target in breast cancer. Elsevier Science 2014-09 /pmc/articles/PMC4127787/ /pubmed/24971713 http://dx.doi.org/10.1016/j.bone.2014.06.023 Text en © 2014 The Authors http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
spellingShingle Original Full Length Article
Haider, Marie-Therese
Holen, Ingunn
Dear, T. Neil
Hunter, Keith
Brown, Hannah K.
Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis
title Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis
title_full Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis
title_fullStr Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis
title_full_unstemmed Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis
title_short Modifying the osteoblastic niche with zoledronic acid in vivo—Potential implications for breast cancer bone metastasis
title_sort modifying the osteoblastic niche with zoledronic acid in vivo—potential implications for breast cancer bone metastasis
topic Original Full Length Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127787/
https://www.ncbi.nlm.nih.gov/pubmed/24971713
http://dx.doi.org/10.1016/j.bone.2014.06.023
work_keys_str_mv AT haidermarietherese modifyingtheosteoblasticnichewithzoledronicacidinvivopotentialimplicationsforbreastcancerbonemetastasis
AT holeningunn modifyingtheosteoblasticnichewithzoledronicacidinvivopotentialimplicationsforbreastcancerbonemetastasis
AT deartneil modifyingtheosteoblasticnichewithzoledronicacidinvivopotentialimplicationsforbreastcancerbonemetastasis
AT hunterkeith modifyingtheosteoblasticnichewithzoledronicacidinvivopotentialimplicationsforbreastcancerbonemetastasis
AT brownhannahk modifyingtheosteoblasticnichewithzoledronicacidinvivopotentialimplicationsforbreastcancerbonemetastasis